scholarly journals Significance of Serum Uric Acid in Children with Pulmonary Arterial Hypertension

2016 ◽  
Vol 1 (1) ◽  
pp. 46-50 ◽  
Author(s):  
Carmen Corina Şuteu ◽  
Theodora Benedek ◽  
Rodica Togănel
Keyword(s):  
Uric Acid ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Right Ventricular ◽  
Serum Uric Acid ◽  
Walk Test ◽  
Echocardiographic Parameters ◽  
Pulmonary Arterial ◽  
6 Minute Walk Test ◽  
Minute Walk

AbstractIntroduction:Pulmonary arterial hypertension (PAH) is a complex disease with poor prognosis. Serum uric acid has been proposed as a potentially non-invasive and objective parameter for prognosis and response to therapy.Objectives:To investigate the potent relationship between serum uric acid levels and functional and echocardiographic parameters in children with PAH.Methods:Serum uric acid levels were measured in 34 children with PAH and were correlated with the functional class, 6-minute walk test, and echocardiographic parameters at baseline and at 12 months follow-up.Results:In pediatric PAH patients serum uric acid levels were higher compared with the control subjects (p = 0.001). In the high uric acid group serum uric acid levels were correlated with 6-minute walk test (p = 0.008), and with several echocardiographic parameters, such as pulmonary vascular resistance (p = 0.04), fractional area change (p = 0.05), left ventricle eccentricity index (p = 0.04), right atrial area (p = 0.03), right ventricle myocardial index (p = 0.01), and pericardial effusion (p = 0.001), markers of right ventricular overload and dysfunction.Conclusions:Serum uric acid levels are easy to collect and measure, and correlate with both functional and echocardiographic parameters that reflect right ventricular dysfunction.

Decrease in Cerebral Oxygen Saturation During the 6-Minute Walk Test in Pediatric Pulmonary Arterial Hypertension

2019 ◽  
Vol 40 (7) ◽  
pp. 1494-1502
Author(s):  
Leman Tekin Orgun ◽  
Zeynep Öztürk ◽  
Fatma Hayvacı Canbeyli ◽  
Dilek Yapar ◽  
Kıvılcım Gücüyener ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Oxygen Saturation ◽  
Cerebral Oxygen Saturation ◽  
Cerebral Oxygen ◽  
Walk Test ◽  
Pulmonary Arterial ◽  
6 Minute Walk Test ◽  
Minute Walk

scholarly journals What Can be Learned in 6 Minutes? 6-Minute Walk Test Primer and Role in Pulmonary Arterial Hypertension

2010 ◽  
Vol 9 (2) ◽  
pp. 107-111 ◽  
Author(s):  
Charles D. Burger ◽  
Tonya Zeiger
Keyword(s):  
Cardiac Output ◽  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Walk Test ◽  
Indirect Measure ◽  
Practical Test ◽  
Maximal Cardiac Output ◽  
Pulmonary Arterial ◽  
6 Minute Walk Test ◽  
Minute Walk

The 6-minute walk test is an easy to perform and practical test that has been used in the assessment of patients with a variety of cardiopulmonary diseases including pulmonary arterial hypertension. The correlation with maximal cardiac output renders the test an indirect measure of right ventricular function in patients with significant pulmonary arterial hypertension. The test has been employed in the majority of studies evaluating the efficacy of pulmonary arterial vasodilators. In addition, the distance walked has been demonstrated to correlate with prognosis. An understanding of the 6-minute walk test indications, logistics, limitations, and interpretation is important to the clinician utilizing this test to evaluate patients with pulmonary arterial hypertension.

scholarly journals P1789 Stress echocardiography in patients with pulmonary arterial hypertension - a pilot study

2020 ◽  
Vol 21 (Supplement_1) ◽  
Author(s):  
K Ptaszynska-Kopczynska ◽  
K Mickiewicz ◽  
M Oleksiuk ◽  
T Michalski ◽  
A Lisowska ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Pulmonary Artery ◽  
Stress Echocardiography ◽  
Right Atrial ◽  
Peak Exercise ◽  
Walk Test ◽  
Echocardiographic Parameters ◽  
Pulmonary Arterial ◽  
6 Minute Walk Test ◽  
Minute Walk

Abstract INTRODUCTION Pulmonary arterial hypertension (PAH) is a rare, progressive disease with poor prognosis. Stress echocardiography (SE) gives an important data on hemodynamic response to exercise. In patients with PAH SE may be useful for the diagnosis and risk assessment but data are lacking. AIM OF STUDY The aim of the study was to analyze exercise-induced response of right heart function and pulmonary artery pressure in patients with PAH. MATERIALS AND METHODS Study group consisted of 15 hemodynamically stable patients, 9 women, aged 22-73 (median- 50), diagnosed with PAH treated at Cardiology Department. The patients were subjected to stress echocardiography on supine cycloergometer and underwent assessment before and at peak-exercise. Moreover the standard parameters of clinical assessment: NT-proBNP, WHO functional class, and 6-minute walk test were analyzed. RESULTS Nine patients were in WHO class III, 4 of them- WHO class II and 2- WHO class I. The median NT-proBNP concentration was 169.3 (IQR 151.2-989.5) pg/ml. 6-Minute Walk Test distance was 455 (428-489) meters. The median workload was 75 (IQR 50-100) Watts and it was the median 54% (IQR 37-62%) of predicted. The echocardiographic parameters assessed in SE at rest and shortly after peak-exercise revealed that RV systolic volume did not significantly differ: 70 (49.8-112.3) vs 71.5 (36.6-110) ml, p = 0.3. Right atrial area decreased from median 21.9 (17.4-27.3) to 19.8 (16.4-22.1) cm2, p = 0.05, whereas right atrial volume did not significantly changed - 80 (47.5-99.5) vs 68 (47.3-78.8) ml, p = 0.13. Further, shortly after exercise tricuspid regurgitation peak gradient (TRPG) significantly increased - 43 (25-76.5) vs 71 (50.5-102) mmHg, p = 0.002. CONCLUSIONS In stable PAH patients supine SE is feasible. Even in advanced WHO functional classes patients were able to exercise. Among echocardiographic parameters TRPG reflecting systolic pulmonary artery pressure showed the biggest difference between baseline and peak-exercise values. SE and seems to be a valuable tool in PAH patients’ assessment.

scholarly journals DOES 6-MINUTE WALK TEST PREDICT CLINICAL EVENTS IN PULMONARY ARTERIAL HYPERTENSION? A META-ANALYSIS OF 22 STUDIES

2012 ◽  
Vol 59 (13) ◽  
pp. E1601
Author(s):  
Gianluigi Savarese ◽  
Stefania Paolillo ◽  
Pierluigi Costanzo ◽  
Francesca Musella ◽  
Fabio Marsico ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Meta Analysis ◽  
Walk Test ◽  
Clinical Events ◽  
Pulmonary Arterial ◽  
6 Minute Walk Test ◽  
Minute Walk

scholarly journals EXPRESS: TORREY, a Phase 2 Study to Evaluate the Efficacy and Safety of Inhaled Seralutinib for the Treatment of Pulmonary Arterial Hypertension

2021 ◽  
pp. 204589402110570
Author(s):  
Robert Frantz ◽  
Raymond L. Benza ◽  
Richard Channick ◽  
Kelly M Chin ◽  
Luke Howard ◽  
...  
Keyword(s):  
Pulmonary Arterial Hypertension ◽  
Arterial Hypertension ◽  
Vascular Remodeling ◽  
World Health ◽  
Walk Test ◽  
Phase 2 ◽  
Efficacy And Safety ◽  
Pulmonary Arterial ◽  
6 Minute Walk Test ◽  
Minute Walk

Aberrant kinase signaling that involves platelet-derived growth factor receptor (PDGFR) α/β, colony stimulating factor 1 receptor (CSF1R), and stem cell factor receptor (c-KIT) pathways may be responsible for vascular remodeling in pulmonary arterial hypertension (PAH). Targeting these specific pathways may potentially reverse the pathological inflammation, cellular proliferation, and fibrosis associated with PAH progression. Seralutinib (formerly known as GB002) is a novel, potent, clinical stage inhibitor of PDGFRα/β, CSF1R, and c-KIT delivered via inhalation that is being developed for patients with PAH. Here, we report on an ongoing Phase 2 randomized, double-blind, placebo-controlled trial (NCT04456998) evaluating the efficacy and safety of seralutinib in subjects with World Health Organization Group 1 Pulmonary Hypertension who are classified as Functional Class II or III. A total of 80 subjects will be enrolled and randomized to receive either study drug or placebo for 24 weeks followed by an optional 72-week open-label extension study. The primary endpoint is the change from baseline to Week 24 in pulmonary vascular resistance by right heart catheterization. The secondary endpoint is the change in distance from baseline to Week 24 achieved in the 6-minute walk test. A computerized tomography substudy will examine the effect of seralutinib on pulmonary vascular remodeling. A separate heart rate monitoring substudy will examine the effect of seralutinib on cardiac effort during the 6-minute walk test.

Sign in / Sign up

Export Citation Format

Share Document